AI-generated summary
This review examined eyelid margin vascularity in meibomian gland dysfunction, drawing on studies published from 2010 to 2024. The authors report that inflammation, oxidative stress and cytokine activity are involved in increased eyelid margin vessels, and that newer imaging such as SS-OCTA can quantify this change. They describe treatments such as intense pulsed light, anti-VEGF agents and cyclosporine as promising, and call for further research to standardize diagnostic criteria.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The abstract describes a narrative review without stated study counts or quality assessment, and the treatments are described as promising rather than proven.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
This review investigates the diagnostic and prognostic significance of telangiectatic meibomian gland dysfunction (MGD), as well as potential therapeutic approaches. A thorough scientific literature search was conducted using various databases. Studies focusing on eyelid vascular changes in MGD published between 2010 and 2024 were reviewed. Paper selection was based on their contribution to the understanding of the pathophysiology, diagnosis, and management of the disease. Ocular surface inflammation, oxidative stress, and cytokine activity are the main molecular pathways involved in the pathophysiology of MGD, which leads to increased eyelid margin vascularity. Newer imaging techniques, especially swept-source optical coherence tomography angiography (SS-OCTA), have enabled quantification and objective visualization of this pathology. Additionally, the classification of MGD into telangiectatic and non-telangiectatic forms aids in treatment customization. Promising treatments targeting vascular abnormalities, such as intense pulsed light (IPL), anti-vascular endothelial growth factor (VEGF) agents, and cyclosporine, have emerged to improve meibomian gland function and reduce inflammation. Eyelid margin vascularity is an important biomarker for the diagnosis and management of MGD. With improved imaging techniques and targeted treatments, clinicians can more precisely evaluate disease severity and offer more effective interventions. Further research is needed to standardize diagnostic criteria, customize treatment protocols, and investigate new therapeutic targets for clinical management.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Inflammation, Oxidative stress, Biomarker. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.